Tag Archives: chronic coronary syndrome

La cirugía parece superior a la angioplastia en pacientes jóvenes

ISCHEMIA Trial: Does Complete Anatomical or Functional Revascularization Modify Anything Compared with Medical Treatment?

ISCHEMIA Trial: Does Complete Anatomical or Functional Revascularization Modify Anything Compared with Medical Treatment?

Chronic coronary syndrome (CCS) has been considered another comorbidity in previous studies, and there has been no significant reduction in cardiovascular mortality or myocardial infarction (MI) rates with revascularization through percutaneous coronary intervention (PCI) or myocardial revascularization surgery (MRS) compared with optimal medical treatment (OMT). One possible reason for the lack of benefit has been

enfermedad carotídea y coronaria severa

5 Year Evolution of PCI vs CABG in Large Randomized Studies on Acute and Chronic Coronary Syndrome

Left main lesions in acute coronary syndrome (ACS) represent a major risk and, at present, the best revascularization strategy is a matter of debate. Though many studies and registries have excluded this group of patients, there is data on the pros and cons of both percutaneous coronary intervention (PCI) and cardiac artery bypass graft (CABG). 

¿Llegó el momento de replantear a la aspirina como la elección en prevención secundaria de MACE?

Should Aspirin Be the Standard of Secondary Prevention of MACE?

Much has been published recently on short term dual antiplatelet therapy (DAPT) both in acute (ACS) and chronic coronary syndrome (CCS) as well as safety of P2Y12 inhibitor monotherapy. When discussing secondary prevention in patients with established coronary artery disease, aspirin (ASA) has been the preferred drug for the prevention of new atherothrombotic events.  This

Top